Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AtriCure (ATRC) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for AtriCure (ATRC) over the last 17 years, with Q3 2025 value amounting to $357000.0.

  • AtriCure's Gains from Investment Securities rose 46666.67% to $357000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $11.1 million, marking a year-over-year increase of 6260.41%. This contributed to the annual value of $7.0 million for FY2024, which is 600.88% up from last year.
  • AtriCure's Gains from Investment Securities amounted to $357000.0 in Q3 2025, which was up 46666.67% from $406000.0 recorded in Q2 2025.
  • Over the past 5 years, AtriCure's Gains from Investment Securities peaked at $15.1 million during Q1 2021, and registered a low of -$189.9 million during Q3 2021.
  • For the 5-year period, AtriCure's Gains from Investment Securities averaged around -$8.1 million, with its median value being $406000.0 (2025).
  • In the last 5 years, AtriCure's Gains from Investment Securities crashed by 9900625.0% in 2021 and then surged by 46666.67% in 2025.
  • Quarter analysis of 5 years shows AtriCure's Gains from Investment Securities stood at -$189.9 million in 2021, then skyrocketed by 100.03% to $65000.0 in 2022, then grew by 29.23% to $84000.0 in 2023, then surged by 128.57% to $192000.0 in 2024, then soared by 85.94% to $357000.0 in 2025.
  • Its Gains from Investment Securities was $357000.0 in Q3 2025, compared to $406000.0 in Q2 2025 and $10.2 million in Q1 2025.